NSE IPO - Apply Online, Check Issue Date, Price, Lot Size & Allotment Status

Apply for NSE IPO:

Skip to main content

Live Fulcrum Therapeutics, Inc. Common Stock Share Price Chart

O H L

Fulcrum Therapeutics, Inc. Common Stock Performance Overview

Days Range
$3.77Low
$3.79High

Markets Today

Previous Close$3.77
Open$3.78
Volume135,047
Day's Range$3.77 - $3.79
52W Range$2.83 - $15.74
Market Cap$289.17 M

Historical Performance

1M Returns-2.58
3M Returns+1.89
6M Returns-45.52
1Y Returns-50.00
5Y Returns-87.77
10Y ReturnsNA

Fulcrum Therapeutics, Inc. Common Stock Fundamentals

Market Cap$289.17 M
Dividend yield0.00
PE Ratio0.00
PEG RatioN/A
Revenue$0.00
ROE TTM-0.25
EPS TTM$-1.21
Quarterly Earnings Growth YOYN/A
PB Ratio0.93
EBITDA$-83.38 M
Profit MarginN/A
Market Cap$289.17 M
Dividend yield0.00
PE Ratio0.00
PEG RatioN/A
Revenue$0.00
ROE TTM-0.25
EPS TTM$-1.21
Quarterly Earnings Growth YOYN/A
PB Ratio0.93
EBITDA$-83.38 M
Profit MarginN/A

Fulcrum Therapeutics, Inc. Common Stock Profit & Loss

Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Total Revenue +$0$0$0$0$0$0
Gross Profit +$0$0$0$0$0$0
Operating Income -$20.40 M-$19.82 M-$21.86 M-$22.69 M-$22.19 M-$29.31 M
EBITDA -$20.05 M-$19.47 M-$21.51 M-$22.35 M-$21.85 M-$19.69 M
Interest Expense $0$2.52 M$0$0$0$3.13 M
Depreciation $353.00 K$344.00 K$346.00 K$347.00 K$338.00 K$9.62 M
Income Before Tax -$17.66 M-$17.30 M-$19.59 M-$20.33 M-$18.89 M-$26.18 M
Income Tax Expense $0$0$0$0$0$0
Net Income +-$17.66 M-$17.30 M-$19.59 M-$20.33 M-$18.89 M-$26.18 M
Net Profit Margin ------

Fulcrum Therapeutics, Inc. Common Stock Financials Balance Sheet In USD

Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Share Capital $54.00 K$54.00 K$54.00 K$67.00 K$67.00 K$76.00 K
Reserve & Surplus -$536.98 M-$554.27 M-$573.70 M-$594.10 M-$613.68 M-$639.91 M
Non-Current Liabilities $6.06 M$5.47 M$4.86 M$4.24 M$3.60 M$2.96 M
Current Liabilities $8.10 M$8.98 M$11.63 M$13.05 M$9.86 M$10.30 M
Total Liabilities $14.16 M$14.46 M$16.49 M$17.28 M$13.47 M$13.26 M
Fixed Assets $3.55 M$3.27 M$3.17 M$2.82 M$2.49 M$0
Current Assets $232.56 M$219.37 M$205.86 M$357.48 M$338.67 M$322.85 M
Total Assets $242.65 M$228.84 M$214.86 M$366.28 M$346.77 M$323.95 M

Fulcrum Therapeutics, Inc. Common Stock Cash Flow

Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Net Income -$17.66 M-$17.30 M-$19.59 M-$20.33 M-$18.89 M-$26.18 M
Operating Cash Flow -$15.26 M-$13.82 M-$14.19 M-$16.80 M-$18.75 M-$16.04 M
Investing Cash Flow -$777.00 K$13.93 M$18.61 M-$1.05 M-$128.21 M$13.78 M
Financing Cash Flow $0$301.00 K$64.00 K$168.30 M-$312.00 K$356.00 K
Change in Cash -$16.03 M$414.00 K$4.49 M$150.46 M-$147.27 M-$1.90 M

Fulcrum Therapeutics, Inc. Common Stock Return Calculator

The Fulcrum Therapeutics, Inc. Common Stock stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Returns Estimator

Based on past performance of this fund

ENTER AMOUNT
$10,000
Select Duration
5Yrs
1 Yr5 Yrs
If you had invested $10,000 5 years ago, what would its value be today?$1,223
Invested Amount$10,000
Est. Returns$-8,777
Invest in USA Stock Today

About Fulcrum Therapeutics, Inc. Common Stock

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.

FAQs

Fulcrum Therapeutics, Inc. Common Stock (FULC) share price as of September 18, 2026 is $3.77. If you are investing from India, you can always check the valuation in the INR before investing.
Yes, Indian Investors can invest in the Fulcrum Therapeutics, Inc. Common Stock (FULC) Share by opening an international trading account with Angel One.
Purchasing Fulcrum Therapeutics, Inc. Common Stock (FULC) share from India can be done by: Directly: By opening an international trading account with Angel One. The process would include KYC verification. The account activation takes a few minutes to a few hours, after which you can start buying Fulcrum Therapeutics, Inc. Common Stock (FULC) by making deposits in US dollars. Indirectly: By investing in mutual funds and Exchange Traded Funds (ETF) that offers exposure in global stocks.
Yes, you can purchase fractional shares of Fulcrum Therapeutics, Inc. Common Stock (FULC) or any other US company shares in Angel One for any dollar amount.
The market capitalization of Fulcrum Therapeutics, Inc. Common Stock on September 18, 2026, is $289.17 M.
Fulcrum Therapeutics, Inc. Common Stock operates in the Healthcare sector, specifically in the Healthcare industry.
In order to invest in Fulcrum Therapeutics, Inc. Common Stock (FULC) you will need Proof of Identification (Aadhaar, PAN, Passport etc.) and Proof of Address (Aadhaar, Voter Card etc.). From start to end, the process is digital and can be seamless.

Diversify Your Portfolio with US Stocks

Invest in Wall Street Giants from India

+91
Top US Stocks

VIEW ALL

Open Free Demat Account!

Join our 3.8 Cr+ happy customers
+91